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Background: Alzheimer’s disease is a neurodegenerative disorder in which extracellular deposition of β-amyloid
(Aβ) oligomers causes synaptic injury resulting in early memory loss, altered homeostasis, accumulation of
hyperphosphorylated tau and cell death. Since proteins in the SNAP (Soluble N-ethylmaleimide-sensitive factor
Attachment Protein) REceptors (SNARE) complex are essential for neuronal Aβ release at pre-synaptic terminals, we
hypothesized that genetically controlled SNARE expression could alter neuronal Aß release at the synapse and
hence play an early role in Alzheimer’s pathophysiology.
Results: Here we report 5 polymorphisms in Vesicle-Associated Membrane Protein 1 (VAMP1), a gene encoding a
member of the SNARE complex, associated with bidirectionally altered cerebellar VAMP1 transcript levels (all p < 0.05).
At the functional level, we demonstrated that control of VAMP1 expression by heterogeneous knockdown in mice
resulted in up to 74% reduction in neuronal Aβ exocytosis (p < 0.001). We performed a case-control association study
of the 5 VAMP1 expression regulating polymorphisms in 4,667 Alzheimer’s disease patients and 6,175 controls to
determine their contribution to Alzheimer’s disease risk. We found that polymorphisms associated with increased brain
VAMP1 transcript levels conferred higher risk for Alzheimer’s disease than those associated with lower VAMP1 transcript
levels (p = 0.03). Moreover, we also report a modest protective association for a common VAMP1 polymorphism with
Alzheimer’s disease risk (OR = 0.88, p = 0.03). This polymorphism was associated with decreased VAMP1 transcript levels
(p = 0.02) and was functionally active in a dual luciferase reporter gene assay (p < 0.01).
Conclusions: Genetically regulated VAMP1 expression in the brain may modify both Alzheimer’s disease risk and may
contribute to Alzheimer’s pathophysiology.
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Despite more than 100 years of research on Alzheimer’s
disease, the search for drugs that are able to slow or stop
disease progression is still ongoing; a search that is fur-
ther compounded by the fact that if such a disease-
modifying drug is to be effective, better understanding* Correspondence: obelbin@santpau.cat
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unless otherwise stated.of the pre-clinical stage of Alzheimer’s disease is essen-
tial. While it is generally accepted that oligomerization
of β-amyloid (Aβ) may be the initiating factor in a cas-
cade of neuronal insults and synaptic injury that ultim-
ately lead to neuronal death and early memory loss [1],
the mechanisms which precede Aβ oligomerization have
yet to be elucidated. One potential mechanism could be
an increase in neuronal secretion of Aβ, which in itself
would presumably have profound effects on synaptic
transmission; Aβ peptides have been shown to bind
synapses [2], reduce spine density [3-8] and depress ex-
citatory transmission [9]. The toxic 42 amino acidl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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availability and release of synaptic vesicles [10]. Moreover,
a feedback loop has been described whereby increased
synaptic activity increases Aβ generation and release [11].
It is evident therefore that a correctly functioning secre-
tion system for Aβ is critical for maintaining synaptic
homeostatic plasticity and that its malfunction could rep-
resent a potential preclinical mechanism that could later
trigger Alzheimer pathophysiology.
In 2008, Cirrito et al., reported that an estimated 70%
of extracellular Aβ arises from the endocytic-exocytic
pathway [11]. Specifically, the full-length amyloid pre-
cursor protein (APP) is endocytosed from the plasma
membrane where it is sequentially processed by β- and
γ-secretases to produce Aβ, which is then secreted from
the cell and the APP intracellular domain, which re-
mains localised to the membrane. Fundamental to this
process are the SNAP (Soluble N-ethylmaleimide-
sensitive factor Attachment Protein) REceptors (SNARE)
proteins, which are located on both the vesicular and
cytoplasmic membranes [12]. Unification of the SNARE
proteins via a common SNARE motif, allows fusion of
the Aβ-containing vesicles with the cytoplasmic mem-
brane at pre-synaptic terminals resulting in Aβ release
[12]. Moreover, the APP intracellular domain has been
demonstrated to directly interact with two SNARE pro-
teins (vesicle-associated membrane proteins; VAMP 1
and 2) within the synaptic vesicles [13], making the
VAMP proteins good candidates for functional control
of Aβ release. With this in mind, we hypothesized that
aberrant SNARE expression may have a direct effect on
the levels of extracellular Aβ. We searched for polymor-
phisms that regulate SNARE expression and found a
strong hit for the neuronal SNARE, VAMP1. Here we
report an in-depth study of the relationship between
VAMP1 polymorphisms and transcriptional VAMP1 ex-
pression in the brain of Alzheimer’s disease patients
and cognitively healthy controls, the correlation be-
tween VAMP1 protein expression and neuronal Aβ
secretion using primary neurons derived from miceTable 1 Summary of the patient samples included in this stud
Total CTRLs
Series N N %F %ε
A) Mayo postmortem 365 173 35.3 26
B) All 10,842 6,175 54.4 23
Mayo Clinic 6,307 4,250 54.0 23
NCRAD 910 209 61.7 16
Norway 927 569 59.6 24
ARUK 2,698 1,147 51.6 24
Demographic details are shown for (A) Samples taken from the cerebellum of auto
analyses and (B) Samples from the Mayo Clinic, Indiana, Norway and Alzheimer’s Re
association study. N; number of samples, %F; percent females, %ε4; percent APOE εheterogeneously expressing VAMP1 and a case-control
association study of 4,667 Alzheimer’s disease patients
and 6,175 controls of Caucasian European descent. Fi-
nally, we tested the functional capacity of the VAMP1
polymorphisms using a dual luciferase reporter gene
assay.
Results
In order to determine whether SNARE expression was
under the transcriptional control of genetic variants, we
searched for single nucleotide polymorphisms associated
with altered SNARE mRNA transcript expression using a
publically available database [14]. The platform included
genotypes for 408,273 polymorphisms and measurements
of 54,675 transcripts in Epstein-Barr virus-transformed
lymphoblastoid cell lines. Our search, which focused on
SNAREs that are robustly expressed in the brain (APBA1,
SNAP25, STX1A, STXP1, VAMP1, VAMP2), revealed a
strong hit for VAMP1. All 8 polymorphisms included on
the platform within VAMP1 and the VAMP1 3′ untrans-
lated region showed unequivocal association with altered
VAMP1 expression (all p < 3.7×10-4; Additional file 1:
Table S1). In order to confirm the association in a more
relevant tissue, we measured VAMP1 mRNA and geno-
typed the VAMP1 region in 365 post-mortem cerebellum
samples (192 AD, 173 controls, Table 1A. For genotype
counts see Additional file 1: Table S2A). To ensure that
we had good coverage of VAMP1, we identified 5 linkage
disequilibrium (LD) blocks within the VAMP1 locus
(Additional file 2: Figure S1) using genotype data from the
Caucasian European (CEU) population published by the
HapMap project (www.hapmap.org). One polymorphism
from each LD block was genotyped (Additional file 2:
Figure S1) giving 80% coverage of all genotyped polymor-
phisms at a minor allele frequency (MAF) >1%. We tested
for association of genotypes at these 5 polymorphisms
with cerebellar VAMP1 transcript levels adjusting for age,
sex and the APOE ε4 allele using dominant, additive
and recessive models (For full data see Additional file 1:
Table S3). The VAMP1 transcript levels grouped byy
AD
4+ Age N %F %ε4+ Age
.0 71.7 192 51.6 63.0 73.5
.4 77.6 4,667 61.1 62.3 76.6
.3 78.7 2,057 60.7 59.9 79.3
.3 78.3 701 64.8 78.5 75.2
.6 74.9 358 69.8 63.1 79.4
.2 74.7 1,551 58.0 58.0 73.0
psy-confirmed AD patients and controls and used for genotype versus mRNA
search UK (ARUK) Consortium case-control series used for the case-control
4 carriers, Age; years.
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phisms were associated with altered VAMP1 transcripts.
The strongest associations were observed for the two
most 3′ variants; rs7390 with increased VAMP1 ex-
pression (-β coefficient = 0.41, p = 4×10-15) and rs12964
(-β coefficient = -0.41, p < 2×10-9) with decreased ex-
pression (for ease of interpretation, the negative value
of the β coefficients are reported here such that a nega-
tive value represents a decrease in expression and a
positive value an increase in expression). These associa-
tions that are equivalent in direction and effect size to
those reported by Dixon et al. in lymphoblastoid cells;
rs7390 -β = 0.51, p = 1×10-9 (same allele tested) and
rs12964 -β = 0.3, p = 3×10-5 (opposing allele tested), in-
dicate that the genetic control of VAMP1 expression is
independent of tissue type. The association of rs7390,
rs12964, rs2072376 and rs2240867 were also confirmed
in both the Alzheimer’s disease (all p < 8.4×10-5) and
control (all p < 2.9×10-3) subsets (Additional file 1:
Table S3), indicating that the transcriptional regulation
is also independent of diagnosis. The exception wasFigure 1 VAMP1 variants are associated with altered VAMP1 transcrip
of the data) plots are shown for VAMP1 mRNA expression (-ΔCT) in 365 cer
genotype (0, 1, 2 = number of copies of the minor allele). For ease of interp
negative value represents a decrease in expression and a positive value an
and p-values (p) for the logistic regression of ΔCT versus VAMP1 genotype
performed following additive, dominant and recessive models; the best mo
AD and Control subsets and for all models tested, see Additional file 1: Tab
The scaled schematic represents the full VAMP1 sequence (line) in the 5′ to
(arrowed box).rs2072376, which was associated with altered expres-
sion in the controls (p = 0.003) but not Alzheimer’s dis-
ease patients (p = 0.8). Expression levels of VAMP1 did
not differ between diagnosis groups (p = 0.41). Overall,
these data suggest that VAMP1 transcription across tis-
sues may be controlled by polymorphisms located at
several locations within VAMP1 and that, in the case of
rs2072376, this regulation may be disrupted in the
Alzheimer’s disease subgroup.
To test our hypothesis that altered VAMP1 expression
in the brain could affect neuronally secreted Aβ levels,
we performed shRNA-mediated knockdown of VAMP1
in primary mouse neurons, achieving a 37.6% reduction
in VAMP1 protein expression (Figure 2A). The levels of
the two most abundant Aβ species (Aβ1-40 and Aβ1-42)
secreted into the cell media were measured by ELISA
after 4 and 8 days of culture (Figure 2A). After 4 days,
we found that secreted Aβ40 and Aβ42 levels were low
in both the non-target neurons treated with scrambled
shRNA and VAMP1 shRNA-treated neurons. However,
by 8 days culture we observed an increase in Aβ40 andt levels in cerebellum. Box (25th-75th percentiles) and whisker (range
ebella samples (pooled Alzheimer’s and controls) grouped by VAMP1
retation, the negative of the ΔCT (-ΔCT) are plotted here such that a
increase in expression. The β co-efficient (-β for ease of interpretation)
(adjusted for age, sex and APOE ε4 allele) are given. Analyses were
del (lowest p-value) for each polymorphism is shown. For results in
le S3. The location of each polymorphism within VAMP1 is indicated.
3′ direction including exons (boxes) and 3′untranlsated region
Figure 2 Lowering VAMP1 transcript and VAMP1 protein expression in primary neurons reduces Aβ secretion. Levels of Aβ40 and Aβ42
species secreted into the media were measured in A) mouse primary neurons subjected to shRNA-mediated knockdown of VAMP1 (VAMP1
shRNA) versus non-target neurons treated with scrambled shRNA (n = 7), and B) mouse primary neurons of transgenic mice with heterogeneous
knockdown of VAMP1 (VAMP1+/-) versus Wild-type mice (n = 6). Media were tested for Aβ at day 4 (d4) and day 8 (d8) of neuronal culture.
C) Soluble Aβ40 and Aβ42 were also measured in brain extracts from Wild-type and VAMP1+/- mice. Bars represent mean values across replicates.
Error bars represent standard error of the mean. *p > 0.05, ***p < 0.0001 for t-test. Representative Western blot images showing reduced VAMP1
expression levels in the VAMP1 shRNA treated versus non-target neurons (A) and in brains of VAMP1+/- and VAMP1-/- versus wild-type mice
(C) are shown.
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treated neurons; VAMP1 shRNA-treated neurons se-
creted 72% less Aβ40 (p < 0.0001) and 81% less Aβ42
(p < 0.0001) than non-target neurons (n = 7). Compared
to other Aβ species, Aβ42 has increased aggregation
properties and is believed to be largely responsible for
the toxic fibrillar aggregates found in the Alzheimer’s
disease brain. Consequently, an increased ratio of Aβ42/
40 species in the brain can be a good indicator of under-
lying Alzheimer’s disease pathology. Notably, we found a
decreased Aβ42/40 ratio in shRNA-treated versus non-
target neurons (0.12 vs 0.17, respectively). To confirm
that this correlation between reduced VAMP1 protein
expression and Aβ secretion was not an indirect effect
of the shRNA knockdown on the functional capacity of
the neurons, we next sought to confirm these findings in
primary neuronal cultures from mice heterogeneously
expressing VAMP1. The VAMP1+/- mice were found to
express 56% less VAMP1 protein than wildtype mice
(Figure 2B). After 4 days culture (Figure 2B), we found a
70% reduction in Aβ40 (p < 0.0001) and 65% reduction in
Aβ42 (p < 0.0001) secreted into the media of VAMP1+/-
versus wt neurons (n = 6). Moreover, similar reductions
were also observed after 8 days of culture (Aβ40 = 74%,
p < 0.0001, Aβ42 = 73%, p < 0.0001). However, unlike in
the previous culture, we found no change in the Aβ42/
40 ratio in neurons of VAMP1+/- mice compared to
those from wt mice (0.16 versus 0.16, respectively at
day 8). These findings in two primary neuronal cultures
support our hypothesis that a decrease in VAMP1protein expression is directly associated with a decrease
in the total levels of Aβ (the pathological protein found
in the Alzheimer’s disease brain) exocytosed from neu-
rons. Moreover, VAMP1 +/- mice had a reduced pool
of soluble Aβ40 and Aβ42 in the brain of 10-day old
VAMP1+/- compared with wildtype mice (Figure 2C),
albeit that is impossible to determine from these brain
extracts whether this reduction in Aβ is due to a reduc-
tion in Aβ secretion or Aβ production.We next sought
to determine whether decreased VAMP1 expression
could have a protective role against developing Alzheimer’s
disease.
In order to determine whether variants that control
VAMP1 expression are associated with altered susceptibil-
ity to late-onset Alzheimer’s disease, we genotyped the 5
VAMP1 polymorphisms in our large case-control series
(Table 1B) of Caucasian European descent from the Mayo
Clinic, National Cell Repository for Alzheimer’s disease
(NCRAD) and Norway (n = 8,144) and utilized the ge-
notypes available for 2 of the polymorphisms from the
Alzheimer’s Research United Kingdom (ARUK) consor-
tium case-control series (n = 2,698). Logistic regression
(adjusting for age, sex and APOE ε4 allele) was performed
for dominant, additive and recessive models (for full data
see Additional file 1: Table S4). Interestingly, as shown in
(Figure 3), the odds ratios (OR) for the polymorphisms as-
sociated with increased cerebellar VAMP1 expression
(rs7390; OR = 1.07 and rs2240867; OR = 0.98, mean OR =
1.025) were significantly higher (p = 0.03) i.e. more carrier
greater risk for Alzheimer’s disease than the polymorphisms
Figure 3 VAMP1 polymorphisms with increased VAMP1 brain expression confer higher risk for Alzheimer’s disease. (A) The odds ratios
and 95% confidence intervals (95% CI) were calculated by binary logistic regression using genotype of 5 common VAMP1 polymorphisms, age,
sex and APOE ε4 allele as predictive variables for diagnosis were performed following additive, dominant and recessive models; the best model
(lowest p-value) for each polymorphism is shown plotted on the y-axis. A significant protective effect of rs2072376 can be seen (OR = 0.88,
p = 0.03). The β-coefficients (+/- standard error of the mean) for the same polymorphisms with cerebellar VAMP1 mRNA expression are plotted on
the x-axis. The polymorphisms associated with increased VAMP1 brain expression (rs7390 and rs2240867) have higher ORs for Alzheimer’s disease
susceptibility than those associated with decreased expression. (B) Meta analyses across subpopulations (Jacksonville; JS, Rochester; RS, Autopsy-confirmed;
AUT) for the rs2072376 polymorphism shows different effect sizes across each population. The population meta-analysis for all samples was not significant
(p = 0.62). (C) The odds ratios and 95% confidence intervals (95% CI) were calculated for 4 rare VAMP1 polymorphisms (adjusted for age, sex and APOE ε4
allele). A significant association was observed for rs74056956 and rs71548434. Meta analyses across subpopulations for rs74056956 (D) and (E) rs71548434
show different effect sizes across each population and were not significant (p = 0.80 and 0.10, respectively). The log10 of the odds ratio and 95% CI are
plotted on the x-axis for better visualization. The populations in which the genotypes deviated from Hardy Weinberg equilibrium are marked by
an asterisk.
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OR = 0.94, rs2072375; OR = 0.89, rs2072376; OR = 0.88,
mean OR= 0.90). However, while significant associations
for variants rs7390, rs2072375 and rs2072376 (p < 0.05)
with altered risk were observed in several of the subpopula-
tions (Additional file 1: Table S4), only the association of
rs2072376 remained (p = 0.03) when analyzing the total
dataset (6,175 controls, 4,667 AD patients) and only when
assuming a recessive model (OR = 0.88, p = 0.03). As shown
in Figure 3B, despite the low heterogeneity of these case-
control series (0%, p = 0.62), the different effect sizes across
the subpopulations meant that the association of rs2072376
did not survive meta-analysis across each series (OR = 0.91,
p = 0.11). Overall, these data are, at best, suggestive of
a common polymorphism, rs2072376 (MAF = 41%), in
VAMP1 that is associated with decreased cerebellarVAMP1 expression that may have a modest protective
effect against Alzheimer’s disease.
We next sought to determine whether rare variants in
the region could be associated with Alzheimer’s disease
susceptibility. Sequencing the 28,440 base pair region con-
taining VAMP1 (+/-20 kb) in 300 Alzheimer’s disease
cases and 300 controls (95% power to detect all variants
with MAF > 1%), we identified 10 variants, 5 of which were
subsequently genotyped in the remaining case-control
series (10,842 samples). Of these 5 variants (all MAF <
0.3%), rs77069473 was discarded due to a minor allele
homozygote frequency higher than that of the heterozy-
gotes (Additional file 1: Table S5). Of the remaining 4
variants, rs74056956 (OR = 2.11, p = 0.05) and rs71584834
(OR = 1.91, p = 0.0006) were associated with increased
Alzheimer’s disease risk (Figure 3C). However, it must be
Sevlever et al. Molecular Neurodegeneration  (2015) 10:18 Page 6 of 12noted that the genotypes deviated from Hardy-Weinberg
equilibrium in several of the subpopulations for both of
these variants (marked by asterisk in Figure 3D for
rs74056956 and Figure 3E and in Additional file 1:
Table S5) and neither association remained following
meta-analyses across the subpopulations. Unfortunately,
due to their low frequency, to determine whether, like
their common counterparts, these rare VAMP1 variants
are associated with altered VAMP1 expression would re-
quire a much larger collection of postmortem samples
than is currently available.
Finally, in order to determine the functionality of the
VAMP1 polymorphisms, we employed a dual luciferase
reporter gene assay to test the best two expression-
associated polymorphisms (rs7390 and rs12964) and the
best Alzheimer’s disease susceptibility polymorphism
(rs2072376) in a human hepatocellular carcinoma line
(HepG2). When comparing the activity of the minor vs
major allelic sequence of the 3 polymorphisms cloned 5′
to the promoter (Figure 4; black bars), changes in re-
porter gene expression were observed in directions con-
sistent with those we report with cerebellar VAMP1
expression for rs7390 (1.3-fold increase; p = 0.01) and
rs2072376 (0.6-fold decrease; p = 0.01). For rs12964, only
a trend towards a 0.9-fold decrease (p = 0.06) was ob-
served. When the sequences were cloned 3′ to the pro-
moter (white boxes), the association of rs2072376 with
decreased reporter gene expression remained (0.5-foldFigure 4 A VAMP1 variant associated with decreased cerebellar
VAMP1 is a functionally active repressor of expression. The
reporter gene expression (ratio of firefly:renilla) for the minor allele
sequence relative to that of the major allele sequence are plotted for
the rs7390, rs12964 and rs2072376 variants transfected in HepG2 cells.
DNA sequences were cloned 5′ (filled boxes) and 3′ (clear boxes) to the
promoter. Unpaired T-tests were used to test for altered reporter gene
expression between major and minor sequences. Error bars represent
SEM (standard error of the mean). *p < 0.05, **p < 0.01 for t-test.decrease; p = 0.007), suggesting that the functional cap-
acity of the rs2072376 sequence is independent of its
relative location to the promoter and is therefore a
strongly suggestive that this is a true functional variant.
These findings demonstrate that the rs2072376 variant,
for which we report an association with decreased cere-
bellar VAMP1 expression and a protective association
with reduced Alzheimer’s disease susceptibility, has
functional repressor activity.
Discussion
Here we have identified a strong association of common
VAMP1 polymorphisms with VAMP1 cerebellar transcript
levels in Alzheimer’s disease and control brains, with the
strongest correlation at the 3′ end of the gene with
increased VAMP1 expression (rs7390 and rs12964, all
p < 2.4×10-7). To put this in a functional context, we de-
monstrated in neuronal cultures that decreased VAMP1
protein expression by shRNA knockdown of VAMP1 is as-
sociated with up to 74% decreased Aβ40 and up to 73%
decreased Aβ42 secretion (p < 0.0001). Notably, we did not
find a significant reduction in Aβ secretion in VAMP1 -/-
compared with wild-type mice (data not shown). This
could indicate that there is a compensatory mechanism for
neuronal secretion in mice when VAMP1 is completely
ablated, which is not apparent in VAMP1+/- mice.
The reduction in extracellular Aβ levels in VAMP1 +/-
neurons is likely due to the role of VAMP1 as part of the
SNARE complex, which is responsible for mediating the
fusion of Aβ-containing vesicles with the pre-synaptic
membrane, resulting in Aβ exocytosis. We propose that as
a consequence of reduced transcriptional expression, re-
duced neuronal VAMP1 protein levels would impede
SNARE complex formation and in turn lead to reduced
recycling of Aβ to the membrane for exocytosis., However,
we cannot rule out other mechanisms by which VAMP1
expression may affect extracellular Aβ levels (e.g. altered
Aβ production, degradation or reuptake).
Since deposition and oligomerization Aβ is a key
pathological hallmark of the Alzheimer’s brain, our data
led us to propose that genetic variation at the VAMP1
locus may be associated with altered susceptibility
against Alzheimer’s disease. Our large case-control asso-
ciation study of 5 independent VAMP1 polymorphisms
in 4,667 Alzheimer’s disease patients and 6,175 controls
revealed that the odds ratio for Alzheimer’s disease sus-
ceptibility was significantly higher for VAMP1 polymor-
phisms associated with increased VAMP1 transcript
expression than for those with decreased VAMP1 tran-
script expression (p = 0.03). Moreover, we report a mod-
est association of a common polymorphism, rs2072376
(MAF = 0.40), located at the 5′ end of VAMP1, with de-
creased risk for Alzheimer’s disease (OR = 0.88, p = 0.03).
This same polymorphism was associated with decreased
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and demonstrated functional repressor activity in vitro
(p < 0.01), thus supporting our hypothesis that decreased
VAMP1 expression may be protective against Alzheimer’s
disease.
This study has primarily focused on the specific role
of VAMP1 in Aβ secretion and its association with
Alzheimer’s disease pathophysiology and susceptibility.
However, it must be noted that haploinsufficiency of
VAMP1 has been reported to cause dominant hereditary
spastic ataxia [15] and that schizophrenic patients have
lower VAMP1 levels in the superior temporal gyrus than
unaffected controls [16]. Furthermore, a null mutation in
VAMP1, which arose spontaneously in C3H/HeSnJ mice,
was associated with muscle wastage, neurological defects
and eventual death [17]. Therefore, while there is a prece-
dent for abnormal VAMP1 expression with several unre-
lated neurological disorders, this is the study is the first to
report a potentially protective effect of VAMP1. This leads
to the possibility that on the one hand, reduced VAMP1
expression can lead to a global dysfunction in neuronal
transmission, which in turn may lead to muscle wastage,
ataxia or schizophrenia, while on the other hand, when
resulting in a specific reduction in neuronal Aβ secretion,
may be protective against Alzheimer’s disease. It would
therefore be interesting, but beyond the scope of this
study, to determine whether individuals with reduced
cerebral VAMP1 expression have other neurological
conditions.
One proviso of this study is that the protective asso-
ciation of rs2072376 with Alzheimer’s disease sus-
ceptibility, as assessed by logistic regression, was modest
(p = 0.03) and did not hold following meta-analyses
across each subpopulation (p = 0.11). Although it must
be noted that unlike the regression, the meta-analyses
cannot take into account other variables (age, sex and
APOE ε4 allele), the meta-analyses do indicate a
population-specific effect size. These findings highlight
the importance of confirming this association in further
independent case-control series before a conclusive as-
sociation between VAMP1 genotype and Alzheimer’s
disease susceptibility can be claimed. Similarly, we re-
port 2 rare variants (MAF < 0.005) that confer risk for
Alzheimer’s disease risk (rs74056956; OR = 0.91 p = 0.05
and rs71584834; OR = 2.11, p = 0.0006) that should be
confirmed in further independent case-control studies.
Conclusions
These data suggest that while the contribution of
VAMP1 genotype to Alzheimer’s disease risk is at best
modest, what is clear is that control of the expression of
this particular SNARE can affect a key cellular process
in the pathophysiology of Alzheimer’s disease by altering
the neuronal secretion of the Aβ peptide. These datapoint towards dysfunctional synaptic recycling of the Aβ
peptide as an early pathological mechanism that could
trigger a series of Aβ-related neuronal insults eventually
leading to Alzheimer’s disease. Consequently, we propose
that genetic variants in genes encoding other SNARE pro-
teins may also be modifiers of Alzheimer’s pathology and/
or susceptibility.
Methods
Ethics statement
Approval was obtained from the ethics committee or re-
view board of each institution responsible for the ascer-
tainment and collection of samples (Mayo Clinic College
of Medicine, Jacksonville, FL and Mayo Clinic College of
Medicine, Rochester, MN, USA, National Cell Reposi-
tory for Alzheimer’s disease, Indianapolis. IN, USA,
Department of Neurology, St. Olav’s Hospital, Norway, De-
partment of Neuroscience, Norwegian University of Science
and Technology, Norway, 7School of Molecular Medical
Sciences, Institute of Genetics, Queen’s Medical Centre,
University of Nottingham, Nottingham and all institutions
in the ARUK consortium). Written informed consent was
obtained for all individuals that participated in this study.
USA case-control subjects
The case-control series consisted of Caucasian subjects of
European descent from the United States ascertained at
the Mayo Clinic (2,057 late-onset Alzheimer’s disease,
4,250 controls) or through the National Cell Repository for
Alzheimer’s Disease (NCRAD: 701 late-onset Alzheimer’s
disease, 209 control). All subjects ascertained at the Mayo
Clinic in Jacksonville, Florida (JS: 868 LOAD, 1,472
controls) and at the Mayo Clinic in Rochester, Minnesota
(RS: 600 late-onset Alzheimer’s disease, 2,408 control)
were diagnosed by a Mayo Clinic neurologist. The neur-
ologist confirmed a Clinical Dementia Rating score of 0 for
all JS and RS subjects enrolled as controls; cases had
diagnoses of possible or probable late-onset Alzheimer’s
disease made according to NINCDS-ADRDA criteria [18].
In the autopsy-confirmed series (AUT: 589 late-onset
Alzheimer’s disease, 370 control) all brains were evaluated
by Dr. Dennis Dickson and came from the brain bank
maintained at the Mayo Clinic in Jacksonville. The diagno-
sis of confirmed Alzheimer’s disease was made according
to NINCDS-ADRDA criteria. All late-onset Alzheimer’s
disease brains analyzed in the study had a Braak score of
4.0 or greater. Brains employed as controls had a Braak
score of 2.5 or lower but often had brain pathology unre-
lated to AD and pathological diagnoses that included vas-
cular dementia, fronto-temporal dementia, dementia with
Lewy bodies, corticobasal degeneration, argyrophilic grain
disease, multi-system atrophy, amyotrophic lateral scler-
osis, and progressive supra-nuclear palsy. No subjects in
this study carried familial Alzheimer’s disease mutations in
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viduals, females and mean age at diagnosis/entry in the
late-onset Alzheimer’s disease cases and controls for each
series are shown in Table 1 and Additional file 1: Table S2.
Norway case-control subjects
Samples from Norway consisted of 358 patients diagnosed
with probable or possible AD and 569 cognitively-normal
controls, all ethnic Norwegians. The patients were neuro-
logical and geriatric patients recruited from the University
Hospital of Trondheim, the district hospital in Namsos
and patients from nursing homes in central Norway. Fur-
ther details regarding thee samples can be found in previ-
ous publications [19,20].
ARUK case-control subjects
Samples from a total of 2,698 subjects were obtained from
seven Alzheimer’s Research UK (ARUK) network centers
(Queen’s University Belfast, University of Bristol, Univer-
sity of Leeds, University of Manchester, University of
Nottingham, the Oxford Project to Investigate Memory
and Ageing (OPTIMA) and University of Southampton)
and the University of Bonn, Germany. All samples were
from subjects who were diagnosed clinically using
NINCDS-ADRDA criteria [18]. All patients with evidence
of an autosomal dominant Alzheimer’s disease trait, or
where a first degree relative had been diagnosed with fa-
milial Alzheimer’s disease, were excluded. Since there were
no controls available for the Manchester series, the
Manchester Alzheimer’s disease samples were combined
with those in the Oxford series when the individual series
were analyzed. The frequency of APOE ε4+ individuals, fe-
males and mean age at diagnosis/entry in the late-onset
Alzheimer’s disease cases and controls for each series are
shown in Table 1 and Additional file 1: Table S2.
DNA isolation
For the Mayo Clinic samples, DNA was isolated from
whole blood using an AutoGen instrument (AutoGen, Inc,
Holliston, MA). The DNA from AUT samples was ex-
tracted from cerebellum using WizardH Genomic DNA
Purification Kits (Promega Corp., Madison, WI). DNA
from the Mayo Clinic Rochester and the autopsy-
confirmed series was scarce, so samples from these two
series were subjected to whole genome amplification using
the Illustra GenomiPhi V2 DNA Amplification Kit (GE
Healthcare Bio-Sciences Corp., Piscataway, NJ). For the
ARUK samples, genomic DNA was extracted from whole
blood samples or brain tissue using the QIAamp DNA
blood mini kit (Qiagen, Crawley, West Sussex, UK).
Genotyping of variants
All genotyping was performed at the Mayo Clinic in
Jacksonville using TaqManH SNP Genotyping Assays inan ABI PRISMH 7900HT Sequence Detection System
with 384-Well Block Module from Applied Biosystems,
California, USA. The genotype data was analyzed using
the SDS software version 2.2.2 (Applied Biosystems,
California, USA). Fifteen percent of the samples assayed
were of known genotype, determined by sequencing and
10% were genotyped in duplicate as a quality assurance
measure. The data were only accepted when there was
100% concordance between duplicate samples. Details of
the variants investigated in this study, including location,
allele frequencies, Hardy-Weinberg equilibrium p-values
and genotype counts can be found in Additional file 1:
Tables S2 and S5.
Sequencing of VAMP1
In each of the 300 subjects screened, we evaluated ampli-
cons that contained a total of 28,440 bp. This DNA in-
cluded all exons, introns, and 20 kb of 5′ and 3′ flanking
sequence. PCR primer pairs were designed to screen the
targeted conserved segments via denaturing high perform-
ance liquid chromatography (dHPLC). PCR amplicons
were generated with 20 ng of DNA in a 50 ul PCR con-
taining 0.2 mM forward primer, 0.2 mM reverse primer,
200 mM dNTPs, 5 ul of 106 reaction buffer with 25 mM
MgSO (Transgenomic, Inc.), and 1 Unit of OptimaseH
Polymerase (Transgenomic, Inc.), using one of the follow-
ing three conditions in a Hybaid thermocycler: 60–50
Touchdown, 62–57 Touchdown, or 55–45 Touchdown.
Each PCR product was denatured at 95 uC for 10 min and
cooled slowly to 25 uC at a rate of 0.03 uC/sec to encour-
age heteroduplex formation. 5 ml of each sample was
injected into a DNASepH HT Cartridge 6.5 mm 637 mm
(Transgenomic, Inc.) and analyzed in a WAVE DHPLC in-
strument (Transgenomic, Inc.) to identify heterozygotes.
The optimal oven temperature and WAVE OptimizedH
buffer gradient for DHPLC analysis of each amplicon was
selected using the Navigator TM4 software (Transgenomic,
Inc.). Samples were categorized as either heteroduplexes or
homoduplexes, based on the resulting elution profiles
as recommended by Transgenomic, Inc. Representative
homoduplexes and heteroduplexes from each amplicon
were sequenced in order to determine the nature of the
DNA variation underlying each heteroduplex profile. 20 ml
of remaining PCR product from the selected samples were
purified for the sequencing reaction using the Multi-
ScreenH PCR96 Filter Plates (Millipore). Sequencing in the
forward and reverse orientation was performed at the Mo-
lecular Biology Core Facility at the Mayo Clinic, Rochester,
MN as described on their website (http://www.mayo.edu/
research/core-resources/molecular-biology-core/services).
Measurement of VAMP1 mRNA Expression
Total RNA was extracted from 365 samples of cerebel-
lum from late-onset Alzheimer’s disease brains and
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Mayo Clinic) using an ABI PRISM 6100 Nucleic Acid Pre-
pStation and the Total RNA Isolation Chemistry kit from
Applied Biosystems. RNA was reverse transcribed to
single-stranded cDNA using the High-Capacity cDNA
Archive Kit from Applied Biosystems. Realtime quantita-
tive PCR was performed in triplicate for each sample using
ABI TaqMan Low Density expression Arrays (384-Well
Micro Fluidic Cards) with a pre-validated TaqMan Gene
Expression Assay. 18 s ribosomal RNA (18 s rRNA) was
used as the endogenous control for the relative quantifica-
tion of VAMP1 mRNA. Real-time PCR cycle threshold
(CT) raw data was collected and exported using the ABI
PRISMH SDS software version 2.2. The variable CT within
the raw data file indicates the PCR cycle number at which
the amount of amplified gene target reaches a fixed
threshold. The variable ΔCT denotes the difference be-
tween the averaged CT values for the VAMP1 transcript
and that for the reference 18S rRNA transcript. The ΔCT
values calculated from each sample were used as quan-
titative phenotypes to determine associations between
VAMP1 genotypes and the level of VAMP1 transcript.
Linkage Disequilibrium (LD) of the VAMP1 region
HaploView 3.1 was used to calculate the extent of LD
between the 15 variants located on chromosome 12 be-
tween positions 6,441,667 and 6,450,104 (VAMP1) with
a minor allele frequency >1% in the European (CEU)
population published by the HapMap project (www.
hapmap.org). An r2 cut-off of 0.8 was used to group
variants into LD blocks. Five LD blocks were identified.
One variant from each block was chosen for genotyping
in this study.
Lenti viral preparation
Five shRNA MISSION RNA interference vectors target-
ing non- and coding VAMP1 regions were obtained
through a partnership agreement between Sigma and the
Mayo Clinic RNA Interference Shared Resource. The
Virapower lentiviral expression kit (Invitrogen) was used
to produce lentiviral particles in the packaging cell line
293FT according to the manufacturer’s protocol. Viral
particles present in the cell culture medium were con-
centrated by centrifugation through a 20% sucrose cush-
ion for 2 h at 20,000 rpm. The pelleted viral particles
were resuspended in PBS and filtered through 0.22 μm
centrifugal filters (Millipore). Titers of the viral pre-
parations were measured using the Lenti-X™ qRT-PCR
Titration Kit from Clontech. Viral preparations of the
five constructs with similar titers (~1010 copies/ml)
were tested in primary neuronal cultures and clone
NM_009496.2-462s1c1 (targeting the coding region of
VAMP1) gave the best knockdown efficiency and was
used in the experiments reported in this paper.Primary neuronal culture and viral infection
The cortex from newborn mouse pups were dissected in
HIBERNATE™ A media without calcium (BrainBits), and
incubated in 1 mg/ml papain (Fisher Scientific) at 30°C
for 30 min. Tissue was dissociated by triturating with a
series of Pasteur pipettes of decreasing diameter. Follow-
ing centrifugation to collect the cell pellet, the cells were
resuspended in Neurobasal A (Invitrogen) supplemented
with B27, GMAX, and bFGF (Invitrogen). Neurons were
seeded at a density of 1 × 106 cells/well in polylysine
coated 6-well plates. To knockdown VAMP1 expression
after 4 days in culture, 1 ml of medium was removed
and 50 μl of viral particles in PBS were added. The fol-
lowing day the virus-containing medium was replaced
with 2 ml of Neurobasal A medium.
Western blot of VAMP1
Primary neuronal cells and mouse brains were extracted
with RIPA buffer (Sigma). Insoluble material was pel-
leted by centrifugation for 5 min at 10,000 g, and the
protein concentration in the supernatants was deter-
mined by BCA assay (Thermo Scientific). Twelve μg of
protein from primary neurons and 30 μg from brain ex-
tracts were loaded on 4-20% gradient Tris-glycine Novex
gels (Life Technologies). The transfer of proteins to
nitrocellulose membranes was carried out at 30 volts for
2 h. The membranes were blocked for 1 h with 5% milk
in PBS, incubated overnight with a rabbit VAMP1 anti-
body (Synaptic Systems) at 1-100 dilution, and finally
with an anti-rabbit HRP antibody for 1 h at room
temperature at 1-2000 dilution. The blots were devel-
oped with SuperSignal West Femto reagent (Pierce), im-
aged with the Fujifilm Luminescent Image Analyzer
LAS4000 System, and the bands were quantitated using
ImageQuant software.
Extraction of soluble Aβ from brain homogenates
Soluble proteins were extracted from mouse brains fol-
lowing a diethlamine (DEA) extraction. Briefly, brains
were homogenized in 0.2% DEA (in 50 mM NaCl) at a
concentration of 100 mg tissue/ml on ice. The homoge-
ates were centrifuged at 100,000 g for 1 hr at 4°C. Super-
natants were removed and neutralized by adding 1/10th
volume 0.5 M Tris HCl pH 6.8 and vortexed. The sol-
uble Aβ peptides were immediately quantified by ELISA.
Aβ ELISA
Levels of Aβ1-40 and Aβ1-42 peptides were quantified
using “INNO-BIA plasma Aβ forms” (Innogenetics NV,
Ghent, Belgium), a multiplex microsphere-based xMAP
technology research use-only reagent kit, on a Luminex
200, according to the manufacturer’s instructions. The
INNO-BIA kit uses monoclonal antibodies covalently
coupled to spectrally specific fluorescent beads to detect
Sevlever et al. Molecular Neurodegeneration  (2015) 10:18 Page 10 of 12Aβn-42 (mAβN; VFFAEDVG and mAβ42; VGGVVIA)
and Aβn-40 (mAβN; VFFAEDVG and mAβ40; VGGVV).
These recognition sites are equivalent in murine and hu-
man APP. Detection of murine Aβ was comparable to that
using the well established Aβ antibodies, BNT77/BAN50
(Aβx-40) and BNT77/BC05 (Aβx-42) that have been used
previously to detect murine Aβ [21].Preparation of VAMP1 constructs for luciferase assay
AttB-tagged PCR products containing VAMP1 sequence
were cloned into a pGL3 vector containing an SV40 pro-
moter and Luciferase gene (Promega) using the Gateway
cloning system (Invitrogen). Three sets of AttB-flanked
primers specific to VAMP1 sequence 25 bp either side of
the three VAMP1 polymorphisms were used to amplify
genomic DNA extracted from individuals known to be
homozygous for the major or minor alleles. PCR reactions
were performed in a reaction mix containing 1×PCR buf-
fer containing 1.5 mM MgCl2 (QIAGEN), 1 mM dNTPs
(Promega), 0.2 μM each primer, 2.5U HotStar Taq DNA
polymerase and 20 ng genomic DNA to a final volume of
25 μl. Amplification conditions were as follows; 5 minutes
at 95°C, followed by 35 cycles of 30 seconds at 95°C, 1 mi-
nute at 54°C (rs7390 and rs2072376) or 58°C (rs12964),
1 minute at 72°C and finally an extension step of 10 mi-
nutes at 72°C. The resultant amplicons (major and minor
allele) were extracted from an ethidium bromide-stained
agarose gel using a QIAquick Spin kit (QIAGEN) and
verified by sequencing (Mayo Clinic, Rochester). The attB-
flanked fragments were integrated via bacterial recombin-
ation into a kanamycin-resistant pDONR 221 vector using
the BP Clonase II system (Invitrogen) to produce an entry
clone. Entry clones were transformed into Library effi-
ciency DH5α chemically competent E.coli (Invitrogen)
and grown on LB agar containing 50 μg/ml kanamycin
overnight at 37°C. Single colonies were picked for inocula-
tion in liquid LB broth containing 50 μg/ml kanamycin
and incubated overnight in a shaking incubator at 37°C.
Plasmids were extracted from the bacterial cells using a
QIAprep spin kit (QIAGEN). Final expression clones were
constructed by recombination of the entry clones with
ampicillin-resistant pGL3 promoter vector using the LR
Clonase II system (Invitrogen). Expression clones were
transformed into DH5α E.Coli and grown on LB agar con-
taining 100 μg/ml ampicillin and single colonies were in-
oculated in LB broth containing 100 μg/ml ampicillin.
Plasmids were extracted using endotoxin-free Zyppy Plas-
mid miniprep kit (Zymo research) and verified by sequen-
cing. Four expression clones were made in total for each
VAMP1 SNP; two constructs for each of the major or
minor sequence positioned either 5′ to the SV40 pro-
moter and luciferase reporter gene or 3′ to the luciferase
gene.Cell culture and transfection of HepG2 cells
Human HepG2 hepatocellular carcinoma immortalized
cell lines were supplied by ATCC. Cells were cultured in
Eagle Minimum Essential Medium (EMEM) supple-
mented with 10% fetal bovine serum, 2 mM L-Glutamine,
1X non-essential amino acids, 1000 U/ml Penicillin-
Streptomycin (Sigma), 2.5 μg/ml Fungizone (Invitrogen).
All cultures were incubated at 37°C in 5% CO2. 3×10
5
cells were plated in 12-well culture plates 24 hours be-
fore transfection. Cells were co-transfected in triplicate
with the VAMP1 luciferase expression clones (con-
structs for each SNP were tested independently) and a
pRL vector (Promega) containing Renilla Luciferase re-
porter gene. Control wells included co-transfection of
pGL3C (containing an SV40 promoter and SV40 en-
hancer) with pRL. On the day of transfection, cells were
washed twice with PBS and media was replaced with
400 μl serum-free EMEM containing 200 ng expression
clone or control vector, 10 ng pRL and transfection re-
agent Tfx-20 (Promega) at a charge ratio of 3:1 (Tfx:
DNA) per well. Transfection mix was pre-incubated for
15 minutes at room temperature. One hour after trans-
fection, 800 μl complete EMEM was added to each
well.Dual luciferase assay
48 hours after transfection, cells were washed twice
with PBS and harvested with 200 μl of 1× Lysis buffer
(Promega) for 20 minutes on a rocking platform. 5 μl
lysate was plated in a white 96-well assay plate. Firefly
and Renilla luciferase signal were measured on a Veri-
tas microplate luminometer (Turner Biosystems) using
the dual luciferase reporter assay system (Promega).
The ratio of Firefly to Renilla luciferase signal was used
to normalize firefly activity for intra-experimental trans-
fection efficiency. Unpaired t-tests comparing mean
relative firefly signal for our expression clones were
performed.Statistical analyses
As the ΔCT trait was found to follow a Gaussian dis-
tribution (Kolmogorov-Smirnov p = 0.19), parametric
analyses were used. Linear regression of VAMP1
mRNA levels (ΔCT) with genotype and logistic regres-
sion of genotype with disease status were performed
assuming dominant, additive and recessive models and
adjusting for possession of the APOE ε4 allele, sex and
age. Meta-analyses (random effects DerSimonian-Laird
method) of the odds ratios and heterogeneity (Tau-square)
for each case-control subseries were performed for
rs2072376 (recessive model), rs74056956 and rs71584834
(dominant model). All statistics were performed using
SPSS v22 software.
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Additional file 1: Table S1. Association of VAMP1 genotypes with VAMP1
mRNA expression in Epstein-Barr virus-transformed lymphoblastoid cell lines as
published previously by Dixon et al. The polymorphism ID (rs), Chromosomal
position (base pairs), allele tested, linkage disequilibrium (LD) block and
association levels (heritability; H2, effect, logarithm of odds; LOD and p-value)
for three VAMP1 mRNA transcripts are shown for polymorphisms lying within
the VAMP1 region. Average VAMP1; average coefficient across all three
transcripts associated with each variant. Table S2. VAMP1 genotype counts
and minor allele frequencies (MAF) in A) postmortem autopsy-confirmed
samples and B) case-control series. Table S3. Association of VAMP1 genotypes
and VAMP1 mRNA transcript levels in postmortem cerebellum samples. The
number of samples and mean deltaCt values for each group (according to
the number of minor alleles assuming dominant, additive or recessive models)
are shown. Linear regression statistics (β co-efficient, +/- standard error, T
statistic and p-value) adjusted for age, sex and APOE ε4 status are shown for
each model. The best model (lowest p-value) for each variant is highlighted in
yellow. Table S4. Association of VAMP1 genotypes with LOAD risk. Linear
regression statistics (β co-efficient, 95% confidence intervals and p-value)
adjusted for age, sex and APOE ε4 status are shown for each variant assuming
a dominant, additive or recessive model. The results are shown for all
combined and each individual series. Table S5. Genotype counts and minor
allele frequencies (MAF) for rare VAMP1 variants in our case-control series.
Additional file 2: Figure S1. Linkage Disequilibrium (LD) between
variants with a minor allele frequency >5% in the VAMP1 and 3′
untranslated region (UTR). Genotype data from the Caucasian European
(CEU) population published at www.hapmap.org. The location of the
polymorphisms (marked by the genotyped alleles) genotyped by
HapMap is provided in the top box. The box also includes the exonic
(yellow box) and UTR (grey box) regions for the 3 common VAMP1
transcripts. Below, the pairwise r2 values are given within each box
(where r2 = 100, no number is shown). The r2 cutoff for grouping
polymorphisms within the same LD block was r2 ≥ 80 (indicated by black
boxes). The LD block assigned to each variant is shown in the white
circles. One variant from each LD block (*) was chosen as a tagging
variant for that block and genotyped in our study. Below, the LD for the
5 variants genotyped in this study is shown based on the genotypes in
our case-control series. Each polymorphsim is labelled with the rs
number, alleles genotyped (MajorMinor) and chromosomal position.
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